Estimating acute urinary retention risk post prostate high dose-rate (HDR) brachytherapy: A clinical-based recursive partitioning analysis
The use of high-dose rate (HDR) brachytherapy in the treatment of prostate cancer is now well established. According to American Society of Clinical Oncology/Cancer Care Ontario brachytherapy guidelines [1], HDR- or Low Dose-Rate brachytherapy should be offered as a boost to external beam radiotherapy (EBRT) in eligible intermediate and high-risk patients and may be an option as monotherapy in patients with more favourable disease.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Lucas C. Mendez, Andrew Loblaw, Hans T. Chung, Chia-Lin Tseng, Ananth Ravi, Gerard Morton Tags: Original Article Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Chia | External Beam Therapy | Men | Prostate Cancer | Radiology